- Home
- VRCA vs KLRS Comparison
VRCA vs KLRS Comparison
Compare VRCA & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | KLRS |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 46.0M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRCA | KLRS |
|---|---|---|
| Price | $6.63 | $8.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $17.00 | ★ $20.67 |
| AVG Volume (30 Days) | ★ 153.2K | 65.3K |
| Earning Date | 03-10-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,829,000.00 | N/A |
| Revenue This Year | $372.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $2.14 |
| 52 Week High | $9.82 | $12.90 |
Technical Indicators
Market Signals| Indicator | VRCA | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 42.21 |
| Support Level | $6.52 | $8.75 |
| Resistance Level | $7.84 | $9.48 |
| Average True Range (ATR) | 0.43 | 0.65 |
| MACD | -0.10 | -0.18 |
| Stochastic Oscillator | 23.25 | 4.50 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.